Patient-Specific Dosing Models With Bayesian Response Updating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical practices rely on generic dosing regimens based on population data, leading to inefficiencies and increased risk of undesirable outcomes due to lack of patient-specific adjustments, particularly for medications with slow response times.
Innovation Solution
A system and method using Bayesian model averaging and forecasting techniques to develop personalized dosing regimens by combining published mathematical models with patient-specific characteristics and observed responses, refining dosing through Bayesian updating.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If generic dosing regimens based on population data are used, then ease of operation is improved, but manufacturing precision deteriorates
Solution Approach 1:
The patent segments the generic population into distinct patient subgroups based on genetic polymorphisms (e.g., CYP2C19 metabolizer status). Instead of applying a single dosing regimen to all patients, the system divides the population into categories such as poor metabolizers, intermediate metabolizers, extensive metabolizers, and ultra-rapid metabolizers, each receiving tailored dosing recommendations. This segmentation enables precise dosing while maintaining ease of operation through automated classification.
Solution Approach 2:
The patent applies local quality by providing customized dosing regimens specific to each patient's genetic profile rather than a uniform approach. The system determines patient-specific pharmacokinetic parameters and dosing recommendations based on individual characteristics such as genotype, age, weight, and renal function. This localized approach ensures optimal dosing precision for each patient while the automated system maintains ease of operation for clinicians.
2Manufacturing precision
If trial-and-error dosing adjustment is used, then dosing precision is improved, but loss of time increases
Solution Approach 1:
The patent performs preliminary action by calculating optimized dosing regimens before treatment begins, based on patient-specific factors including genetic polymorphisms, age, weight, and renal function. The system uses pharmacokinetic modeling to predict individual drug metabolism and clearance rates, then determines the optimal initial dose and dosing interval in advance. This eliminates the need for trial-and-error adjustments during treatment, achieving dosing precision immediately while reducing the time to optimize dosing.
Solution Approach 2:
The patent implements feedback mechanisms where actual patient drug concentration measurements and clinical responses are continuously monitored and fed back into the pharmacokinetic model. The system compares predicted versus observed drug levels, then adjusts future dosing recommendations accordingly. This closed-loop feedback enables real-time optimization of dosing precision without requiring lengthy trial-and-error periods, as the model learns from actual patient responses and refines predictions.
3Manufacturing precision
If patient-specific dosing is implemented, then dosing precision is improved, but device complexity increases
Solution Approach 1:
The patent introduces an intermediary computational system that acts as a bridge between complex pharmacokinetic modeling and simple clinical decision-making. The system includes automated algorithms that integrate multiple patient factors (genotype, demographics, lab values) and pharmacokinetic parameters to calculate dosing recommendations. This intermediary layer handles the complexity of population pharmacokinetic modeling, Bayesian estimation, and genetic polymorphism analysis, while presenting simplified dosing guidance to clinicians. The intermediary software module manages the computational complexity, enabling dosing precision without burdening the clinical workflow with system complexity.
4Ease of manufacture
If population-based dosing information is used, then ease of manufacture is improved, but reliability deteriorates
Solution Approach 1:
The patent applies parameter changes by transforming fixed population-based dosing parameters into dynamic patient-specific parameters. The system estimates individual pharmacokinetic parameters (clearance, volume of distribution, half-life) using Bayesian methods that combine population average values with patient-specific measurements. Genetic polymorphism data serves as a key parameter that fundamentally changes the predicted metabolism rate and optimal dosing. This parameter transformation maintains ease of manufacture through automated calculation while significantly improving treatment effectiveness and reliability by accounting for individual variability in drug response.
Data Source
AI summary
A system and method for predicting, proposing and/or evaluating suitable medication dosing regimens for a specific individual as a function of individual-specific characteristics and observed responses of the specific individual. Mathematical models of observed patient responses are used in determining an initial dose. The system and method use the patient's observed response to the initial dose to refine the model for use to forecast expected responses to proposed dosing regimens more accurately for a specific patient. More specifically, the system and method uses Bayesian averaging, Bayesian updating and Bayesian forecasting techniques to develop patient-specific dosing regimens as a function of not only generic mathematical models and patient-specific characteristics accounted for in the models as covariate patient factors, but also observed patient-specific responses that are not accounted for within the models themselves, and that reflect variability that distinguishes the specific patient from the typical patient reflected by the model.